Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive
ELEVATE Study: A Phase II Single-Arm Open-Label Single-Center Exploratory Trial of Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Advanced Refractory Solid Tumors With EGFR-Positive
Tianjin Medical University Second Hospital
32 participants
Aug 1, 2026
INTERVENTIONAL
Conditions
Summary
This phase II trial evaluates the combination of Becotatug Vedotin (MRG003), an EGFR-targeting ADC, and Pucotenlimab (HX008), a PD-1 inhibitor, in patients with high EGFR expressing advanced refractory solid tumors. The study is designed to assess clinical efficacy and safety, building on a strong synergistic rationale and promising early-phase data.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Becotatug Vedotin will be given at a dose of 2.0 mg/kg via intravenous infusion on Day 1 of every 3 week cycle (Q3W).
Pucotenlimab will be administered intravenously at 3.0 mg/kg (or as a flat dose of 200 mg) also on Day 1 of each Q3W cycle.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07712029